Alnylam Clinical Trials Finder

People Like You Power Progress Against Disease

We’re working every day to develop innovative new medicines for a broad range of rare and more common diseases. But we can’t do it alone. The process of developing new treatments relies on many groups of people, including, most importantly, those who participate in clinical trials.

We invite you to learn more about our current and prior clinical trials below, and about clinical research at Alnylam.

PATISIRAN (hATTR Amyloidosis)

TRIAL STATUS

COMPLETED

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

ALN-TTR02-002

LOCATION(S):

USA, Brazil, France, Germany, Portugal, Spain, Sweden, Portugal

TRIAL STATUS

COMPLETED

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

ALN-TTR02-003

LOCATION(S):

USA, Brazil, France, Germany, Portugal, Spain, Sweden

TRIAL STATUS

COMPLETED

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

ALN-TTR02-004

LOCATION(S):

USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom

TRIAL STATUS

ACTIVE, NOT RECRUITING

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

ALN-TTR02-006

LOCATION(S):

USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom

TRIAL STATUS

COMPLETED

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

ALN-TTR02-008

LOCATION(S):

Italy, Sweden, Portugal, United Kingdom, Germany, Spain, France

DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:

TRIAL STATUS

RECRUITING

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

ALN-TTR02-010

LOCATION(S):

USA, Portugal, Italy, Spain, France, Germany, Netherlands

TRIAL STATUS

ACTIVE, NOT RECRUITING

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

ALN-TTR02-011

LOCATION(S):

USA, Czechia, Denmark, Sweden, Argentina, Brazil, South Korea, Italy, Taiwan, United Kingdom, France, Japan, Hong Kong, Australia, Mexico, Bulgaria, Chile, Belgium, Netherlands, New Zealand

TRIAL STATUS

COMPLETED

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

ALN-TTR02-012

LOCATION(S):

USA

TRIAL STATUS

RECRUITING

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

ALN-TTR02-013

LOCATION(S):

USA, Portugal, France, Israel, Italy, Netherlands, Spain, Denmark, Germany

GIVOSIRAN (Acute Hepatic Porphyria)

TRIAL STATUS

COMPLETED

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

ALN-AS1-001

LOCATION(S):

USA, Sweden, United Kingdom

TRIAL STATUS

COMPLETED

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

ALN-AS1-002

LOCATION(S):

USA, Sweden, United Kingdom

TRIAL STATUS

COMPLETED

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

ALN-AS1-003

LOCATION(S):

USA, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Spain, Sweden, Taiwan, United Kingdom

DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:

TRIAL STATUS

RECRUITING

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

ALN-AS1-006

LOCATION(S):

USA, France, Germany, Italy, United Kingdom

TRIAL STATUS

COMPLETED

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

ALN-AS1-NT-001

LOCATION(S):

USA, Australia, Belgium, Bulgaria, Czechia, Finland, France, Germany, Italy, Israel, Mexico, Netherlands, Norway, Poland, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom

INCLISIRAN (Hypercholesterolemia)

TRIAL STATUS

COMPLETED

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

ALN-PCSSC-001

LOCATION(S):

United Kingdom

LUMASIRAN (Primary Hyperoxaluria)

TRIAL STATUS

COMPLETED

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

ALN-GO1-001

LOCATION(S):

USA, United Kingdom, Germany, Israel, Netherlands

TRIAL STATUS

ACTIVE, NOT RECRUITING

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Patients With Primary Hyperoxaluria Type 1

ALN-GO1-002

LOCATION(S):

France, Germany, Netherlands, United Kingdom, Israel

TRIAL STATUS

ACTIVE, NOT RECRUITING

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)

ALN-GO1-003

LOCATION(S):

USA, United Kingdom, France, Germany, Netherlands, Switzerland, Israel, UAE

DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:

TRIAL STATUS

ACTIVE, NOT RECRUITING

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

ALN-GO1-004

LOCATION(S):

USA, United Kingdom, France, Germany, Israel

DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:

TRIAL STATUS

ACTIVE, NOT RECRUITING

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

ALN-GO1-005

LOCATION(S):

Israel, USA, France, Belgium, United Arab Emirates(UAE), Netherlands, Turkey, Australia, Jordan, Lebanon, United Kingdom, Italy

TRIAL STATUS

RECRUITING

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

ALN-GO1-007

LOCATION(S):

USA, Belgium

TRIAL STATUS

RECRUITING

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

ALN-GO1-008

LOCATION(S):

USA, Italy

CEMDISIRAN (Complement-Mediated Diseases)

TRIAL STATUS

COMPLETED

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

ALN-CC5-001

LOCATION(S):

Spain, United Kingdom

TRIAL STATUS

ACTIVE, NOT RECRUITING

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

ALN-CC5-005

LOCATION(S):

Canada, Philippines, Spain, Sweden, United Kingdom, Singapore, France, Malaysia, Taiwan

VUTRISIRAN (ATTR Amyloidosis)

TRIAL STATUS

ACTIVE, NOT RECRUITING

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

ALN-TTRSC02-002

LOCATION(S):

USA, Argentina, Bulgaria, France, Portugal, Malaysia, Cyprus, Germany, Japan, South Korea, Greece, Sweden, United Kingdom, Taiwan, Belgium, Mexico, Italy, Australia, Canada, Netherlands, Spain, Brazil

TRIAL STATUS

ACTIVE, NOT RECRUITING

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

ALN-TTRSC02-003

LOCATION(S):

USA, Latvia, Spain, France, Sweden, Lithuania, Portugal, Australia, Republic of Korea, Germany, Norway, United Kingdom, Israel, Hungary, Denmark, Ireland, Canada, Moldova, Austria, Poland, Netherlands, Belgium, Croatia, Peru, Argentina, Japan, Malaysia, Thailand, Colombia, Czechia

ALN-AAT02 (Alpha-1 Liver Disease)

TRIAL STATUS

TERMINATED

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

ALN-AAT02-001

LOCATION(S):

United Kingdom

ZILEBESIRAN (Hypertension)

TRIAL STATUS

ACTIVE, NOT RECRUITING

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

ALN-AGT01-001

LOCATION(S):

United Kingdom

TRIAL STATUS

RECRUITING

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

ALN-AGT01-002

LOCATION(S):

USA, Canada, Ukraine, Puerto Rico, United Kingdom

TRIAL STATUS

RECRUITING

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

ALN-AGT01-003

LOCATION(S):

USA, Canada, Estonia, Poland, United Kingdom, Latvia, Lithuania

ALN-LEC (LECT2 Amyloidosis)

TRIAL STATUS

TERMINATED

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

ALN-LECT2-NT-001

LOCATION(S):

USA, United Kingdom, India, Malaysia, Mexico, Egypt

ALN-APP (Alzheimer’s Disease & Cerebral Amyloid Angiopathy)

TRIAL STATUS

RECRUITING

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

ALN-APP-001

LOCATION(S):

Canada

ALN-XDH (Gout)

TRIAL STATUS

RECRUITING

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

ALN-XDH-001

LOCATION(S):

United Kingdom

Alnylam provides lay summaries as part of our commitment to transparency and ensuring our clinical trial information is accessible to patients, health care providers, researchers and the general public. These summaries represent the results from individual studies and may not represent all of the information about the therapy studied; other studies may have different results. Plain language summaries are not intended for promotional purposes or indication, to guide treatment decisions, or to replace the advice of a healthcare professional. You should not change your therapy based on the results of these studies. Always consult with your health care provider about your treatment options and any questions you may have.